Cargando…

FAP promotes clear cell renal cell carcinoma progression via activating the PI3K/AKT/mTOR signaling pathway

OBJECTIVE: Herein, we aimed at exploring the FAP expression in clear cell renal cell carcinoma (ccRCC) along with its clinical implication. METHODS: Using computational tools analysis of different freely accessible gene databases, the expression pattern, clinical importance, co-expressed genes, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Kun, Xu, Li-zhe, Ning, Jin-zhuo, Cheng, Fan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523722/ https://www.ncbi.nlm.nih.gov/pubmed/37752545 http://dx.doi.org/10.1186/s12935-023-03073-8

Ejemplares similares

Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma
por: Fan, Demin, et al.
Publicado: (2020)

METTL13 inhibits progression of clear cell renal cell carcinoma with repression on PI3K/AKT/mTOR/HIF-1α pathway and c-Myc expression
por: Liu, Zhuonan, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas
por: Lisi, Lucia
Publicado: (2020)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma
por: Zheng, Zaosong, et al.
Publicado: (2019)

PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review)
por: Miricescu, Daniela, et al.
Publicado: (2021)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway
por: Feng, Guofei, et al.
Publicado: (2023)

The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
por: Su, Hengchuan, et al.
Publicado: (2013)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
por: Fransecky, Lars, et al.
Publicado: (2015)

PI3K/AKT/mTOR pathway in pulmonary carcinoid tumours
por: Zhang, Zixuan, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula
por: Ratti, Stefano, et al.
Publicado: (2022)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway
por: Xie, Jinlin, et al.
Publicado: (2018)

PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo
por: Ye, Xueting, et al.
Publicado: (2020)

The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII
por: Chen, Liangmei, et al.
Publicado: (2023)

Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations
por: Krencz, Ildiko, et al.
Publicado: (2021)

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
por: Edlind, Merritt P, et al.
Publicado: (2014)

EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling
por: Xu, Meng, et al.
Publicado: (2017)

LGR6 promotes the progression of gastric cancer through PI3K/AKT/mTOR pathway
por: Ke, Jing, et al.
Publicado: (2018)

Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress
por: Duan, Yi, et al.
Publicado: (2020)

LHPP suppresses gastric cancer progression via the PI3K/AKT/mTOR signaling pathway
por: Wang, Danfang, et al.
Publicado: (2022)

Peptide ARHGEF9 Inhibits Glioma Progression via PI3K/AKT/mTOR Pathway
por: Huang, Jie, et al.
Publicado: (2023)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis
por: Ge, Fengmei, et al.
Publicado: (2017)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
por: Darici, Salihanur, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
por: Tian, Ling-Yu, et al.
Publicado: (2023)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

NVP-BEZ235 Inhibits Renal Cell Carcinoma by Targeting TAK1 and PI3K/Akt/mTOR Pathways
por: Li, Bihui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9m4re765j8mm3i4jh8mf5aqfg1